135 related articles for article (PubMed ID: 32738776)
1. Personalized treatment planning in eye brachytherapy for ocular melanoma: Dosimetric analysis on ophthalmic structure at risk.
Itta F; Liuzzi R; Farella A; Porri G; Pacelli R; Conson M; Oliviero C; Buonanno F; Breve MA; Cennamo G; Clemente S; Cella L
Phys Med; 2020 Aug; 76():285-293. PubMed ID: 32738776
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
3. MRI-based treatment planning and dose delivery verification for intraocular melanoma brachytherapy.
Zoberi JE; Garcia-Ramirez J; Hedrick S; Rodriguez V; Bertelsman CG; Mackey S; Hu Y; Gach HM; Rao PK; Grigsby PW
Brachytherapy; 2018; 17(1):31-39. PubMed ID: 28818442
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma.
Dean MK; Studenski MT; Paez-Escamilla MA; Walter SD; Kwon D; Markoe AM; Harbour JW; Samuels SE
Brachytherapy; 2019; 18(3):404-410. PubMed ID: 30797699
[TBL] [Abstract][Full Text] [Related]
5. EyeDose: An open-source tool for using published Monte Carlo results to estimate the radiation dose delivered to the tumor and critical ocular structures for
Deufel CL; McCauley Cutsinger S; Corbin KS; Dalvin LA; Petersen IA
Brachytherapy; 2021; 20(1):189-199. PubMed ID: 33187821
[TBL] [Abstract][Full Text] [Related]
6. Incorporating patient-specific CT-based ophthalmic anatomy in modeling iodine-125 eye plaque brachytherapy dose distributions.
Tien CJ; Astrahan MA; Kim JM; Materin M; Chen Z; Nath R; Liu W
Brachytherapy; 2017; 16(5):1057-1064. PubMed ID: 28778599
[TBL] [Abstract][Full Text] [Related]
7. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.
Morrison H; Menon G; Larocque MP; Jans HS; Weis E; Sloboda RS
Med Phys; 2016 Aug; 43(8):4891. PubMed ID: 27487906
[TBL] [Abstract][Full Text] [Related]
8. Influence of tumor shape and location in eye plaque brachytherapy dosimetry.
Studenski MT; Patel NV; Markoe A; Harbour JW; Samuels SE
Brachytherapy; 2020; 19(2):249-254. PubMed ID: 32061535
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric benefit of a new ophthalmic radiation plaque.
Marwaha G; Wilkinson A; Bena J; Macklis R; Singh AD
Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1226-30. PubMed ID: 22658440
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of choroidal melanomas treated with eye physics plaques: A 25-year review.
Le BHA; Kim JW; Deng H; Rayess N; Jennelle RL; Zhou SY; Astrahan MA; Berry JL
Brachytherapy; 2018; 17(6):981-989. PubMed ID: 30082188
[TBL] [Abstract][Full Text] [Related]
12. Treatment plan optimization and robustness of
Heilemann G; Fetty L; Dulovits M; Blaickner M; Nesvacil N; Georg D; Dunavoelgyi R
Radiother Oncol; 2017 Apr; 123(1):119-124. PubMed ID: 28185660
[TBL] [Abstract][Full Text] [Related]
13. Investigating the dosimetric impact of seed location uncertainties in Collaborative Ocular Melanoma Study-based eye plaques.
Johnson JE; Deufel CL; Furutani KM
Brachytherapy; 2016; 15(5):661-8. PubMed ID: 27475484
[TBL] [Abstract][Full Text] [Related]
14. Monte Carlo dosimetry modeling of focused kV x-ray radiotherapy of eye diseases with potential nanoparticle dose enhancement.
Yan H; Ma X; Sun W; Mendez S; Stryker S; Starr-Baier S; Delliturri G; Zhu D; Nath R; Chen Z; Roberts K; MacDonald CA; Liu W
Med Phys; 2018 Oct; 45(10):4720-4733. PubMed ID: 30133705
[TBL] [Abstract][Full Text] [Related]
15. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
Richards Z; Nguyen ML; Kutteh M; Ahmad S; Henson C; Firestone B; Herman TS; Herman TF
Med Dosim; 2022 Autumn; 47(3):273-279. PubMed ID: 35644778
[TBL] [Abstract][Full Text] [Related]
16. [Brachytherapy of ocular melanoma: physical and dosimetric aspects of 125I plaques].
Bard JJ
Bull Cancer Radiother; 1995; 82(3):295-305. PubMed ID: 8554879
[TBL] [Abstract][Full Text] [Related]
17. Quantifying the dosimetric influences of radiation coverage and brachytherapy implant placement uncertainty on eye plaque size selection.
Gagne NL; Rivard MJ
Brachytherapy; 2013; 12(5):508-20. PubMed ID: 23466357
[TBL] [Abstract][Full Text] [Related]
18. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques.
Puusaari I; Heikkonen J; Kivelä T
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3425-34. PubMed ID: 15452045
[TBL] [Abstract][Full Text] [Related]
19. Radiobiology for eye plaque brachytherapy and evaluation of implant duration and radionuclide choice using an objective function.
Gagne NL; Leonard KL; Rivard MJ
Med Phys; 2012 Jun; 39(6):3332-42. PubMed ID: 22755715
[TBL] [Abstract][Full Text] [Related]
20. A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using
Lee YC; Lin SC; Kim Y
Radiat Oncol; 2018 Nov; 13(1):221. PubMed ID: 30424782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
